

Company registration number: 60460

**Muscular Dystrophy Ireland
(A Company Limited by Guarantee and not having Share Capital)**

Financial statements

for the financial year ended 31 December 2017

Muscular Dystrophy Ireland
(A Company Limited by Guarantee and not having Share Capital)

Contents

	Page
Directors and other information	1
Directors' report	2 - 12
Directors' responsibilities statement	13
Independent auditor's report to the members	14 - 16
Statement of Financial Activities	17
Statement of financial position	18 - 19
Statement of cash flows	20
Notes to the financial statements	21 - 34

**Muscular Dystrophy Ireland
Company limited by guarantee**

Directors and other information

Directors	Garry Toner Helen McDonnell Hazel Bridcut Maureen Brennan (Resigned 3rd July 2017) Derek Farrell (Resigned 13th May 2017) Grace Greene Ephraim Purcell (Appointed 13th May 2017) John Roche (Appointed 13th May 2017)
Secretary	Hazel Bridcut
Company number	60460
Registered office	75 Lucan Road Chapelizod Dublin 20
Business address	75 Lucan Road Chapelizod Dublin 20
Auditor	Hunt & Company Accountants Limited 52 Manor Street Dublin 7
Bankers	Bank of Ireland 2 College Green Dublin 2
Solicitors	Sherrys Solicitors Palmerstown Avenue Palmerstown Dublin 20
Charity Regulator Number	20012038

Muscular Dystrophy Ireland
(A Company Limited by Guarantee and not having Share Capital)

Directors' report

The directors present their annual report and the audited financial statements of the company for the financial year ended 31 December 2017.

Directors

The names of the persons who at any time during the financial year were directors of the company are as follows:

Garry Toner
Helen McDonnell
Hazel Bridcut
Maureen Brennan (Resigned 3rd July 2017)
Derek Farrell (Resigned 13th May 2017)
Grace Greene
John Roche (Appointed 13th May 2017)
Ephraim Purcell (Appointed 13th May 2017)

Principal activities

The principal activity of the company is to provide information, advice and support to people with Muscular Dystrophy and allied neuromuscular conditions, and their families through a range of support services.

Mission Statement

Muscular Dystrophy Ireland aims to provide information and support to people with neuromuscular conditions and their families through a range of support services. Muscular Dystrophy Ireland's Objective is to promote through practical empowerment, independent living for people with the condition muscular dystrophy.

Muscular Dystrophy Ireland supports advocating for services to enable people with neuromuscular conditions to fully participate in society and to live a life of their own choosing. Muscular Dystrophy Ireland also aims to support and fund research into neuromuscular conditions.

Muscular Dystrophy Ireland
(A Company Limited by Guarantee and not having Share Capital)

Directors' report (continued)

STRUCTURE, GOVERNMENT AND MANAGEMENT

The Council and Board

Muscular Dystrophy Ireland is conducted in accordance with its Memorandum and Articles of Association which were adopted in November 1977 and amended up to and including 29th May 2009.

Muscular Dystrophy Ireland is directed by a voluntary board which is known as the Executive Committee. The Executive Committee comprises a Chairperson, Vice Chairperson, Treasurer, Secretary and there is allocation for a further three members. This Executive Committee meets once a month to determine the management, good governance and financial control of Muscular Dystrophy Ireland. The Executive is provided with regular financial and operational information.

The Executive Committee met on 10 occasions during the year.

The Executive Committee travel expenses in attending meetings in 2017 were €509.

The governance structure of Muscular Dystrophy Ireland is unusual in that instead of a Board there is a National Executive and a National Council, who share the same officers. The National Executive members, who also sit on the National Council, are charged with managing the business and are Directors of the company.

Expert legal opinion has determined that both the members of the National Executive and the members of the National Council share the same legal obligations, accountabilities and liabilities.

To ensure that Muscular Dystrophy Ireland's governance structure remains compliant with the commencement of the Companies Act 2014 and the commencement of the Charities Act 2009 and the formal establishment of the Charities Regulator, it is necessary to review governance structures as a matter of priority.

Accordingly, the following motion was presented to the membership of Muscular Dystrophy Ireland at the AGM held on the 13th May 2017.

"That the National Executive conducts a review of the constitution of Muscular Dystrophy Ireland and makes recommendations to the members of any amendments to the constitution which it considers, in the interests of Muscular Dystrophy Ireland, to be desirable"

This motion was agreed and passed by the members.

The following committees are appointed by The Executive to assist in the operational workings of the organisation.

Finance and Audit Committee
Research Committee
Trust Fund Committee

Muscular Dystrophy Ireland
(A Company Limited by Guarantee and not having Share Capital)

Directors' report (continued)

Management

Muscular Dystrophy Ireland has six regional offices, in Cork, Donegal, Galway, Mullingar, Kells, and Limerick. There are also Muscular Dystrophy Ireland staff members based in the southeast region. Family support is available throughout all HSE regions of Ireland, while youth support is available in the east, south, west, midlands, northeast, northwest, and southeast.

The Chief Executive is responsible for the day to day management and operation of the organisation throughout the National Office and Regional Offices. The National Office is the base for all administration and support services of the organisation.

During the year under review the Chief Executive position was held by Mr. Richard Lodge and in the interim by Mr. Tom Nolan.

Code of Governance

Muscular Dystrophy Ireland signed the Governance Code Principles Statement in March 2013 and confirms that "our organisation complies with The Governance Code for the Community, Voluntary and Charitable Sector in Ireland".

Muscular Dystrophy Ireland adopted the ICTR Guiding Principles for Fundraising and follow these principles.

Muscular Dystrophy Ireland review on an ongoing basis their policy and procedures in order to maintain compliance with the Governance Code.

Funding

Muscular Dystrophy Ireland provides services under Service Level Agreements with Nine CHO Areas. Counselling and Bereavement services were funded through TUSLA. Employee Supports was funded through Department of Social Protection Wage Subsidy Scheme (WSS). Funding from HSE represented 82% of overall incoming resources in 2017.

REVIEW OF ACTIVITIES

INFORMATION

A key function of Muscular Dystrophy Ireland is to provide accurate and relevant information to people with neuromuscular conditions, their families, healthcare and education professionals and the general public. Muscular Dystrophy Ireland's Information Officer is based in the Head Office in Dublin and provides a nationwide service.

In 2017 the Information Officer responded to over 300 individual requests for information. In some circumstances, the Information Officer is the first point of contact for persons new to the organisation following a diagnosis of a neuromuscular condition and 44 information packs were sent to families new to the organisation in 2017.

Muscular Dystrophy Ireland
(A Company Limited by Guarantee and not having Share Capital)

Directors' report (continued)

PRESENTATIONS/INFORMATION TALKS

Muscular Dystrophy Ireland's Information Officer is also available to give presentations about Muscular Dystrophy Ireland and neuromuscular conditions to schools, medical professionals and students etc. Educating allied and emerging health professionals is an important part of the work Muscular Dystrophy Ireland does in creating awareness of Neuromuscular Conditions .

In 2017, 15 information and awareness presentations were given to the following groups:

Teachers and Special Needs Assistants in 5 schools in Louth, Wexford, Dublin and Cork
Social Care Workers in Solis NMC
The School of Nursing in DCU
The staff of Mount Pleasant Nursing Home in Kilcock, Co. Kildare
The Home from Home Facility was used as a resource in educating a group of students studying Disability Studies and Social Policy from Inchicore College with a tour of the building and an information talk
An information stand set up at the Neurological Summit in the City West Hotel on the 25th of May 2017.

On the 13th of May 2017 Muscular Dystrophy Ireland Organised a National Conference and AGM in The Gibson Hotel, Dublin 2. The Agenda included talks on accessible travel and assistive technology, which were followed by workshops on Independent Living and Mental Health Awareness.

The Information Officer also attends conferences on a range of topics and conditions and reports this information back to members. In November 2017, the Information Officer and the Family Support Co-ordinator attended the Action Duchenne Conference in Birmingham.

ADVOCACY

Patient Advocacy and Influencing Policy has become an increasing part of Muscular Dystrophy Ireland's Information Service. Much of this advocacy was focussed on access to the new and innovative treatments now available for Duchenne Muscular Dystrophy.

In June 2017, our Information Officer was invited to speak at an IPPOSI Event in the Irish Human Rights Commission on the topic of access to orphan drugs. Muscular Dystrophy Ireland were also invited as expert witnesses in the Oireachtas Joint Committee on Health Meeting on access to orphan drugs on 12th July 2017.

Muscular Dystrophy Ireland's TD Lobby Day on the 28th September 2017 was an opportunity for our members to meet their local politicians in an accessible environment close to Leinster House. Thirty TD's and Senators in attendance had a valuable opportunity to meet their constituents and Muscular Dystrophy Ireland staff working in their area.

A briefing document and pre- budget submission was issued to all politicians for inclusion in their manifesto.

On the 3rd of October 2017 Muscular Dystrophy Ireland supported members in a meeting in the AV Room in Leinster House in a campaign for access to Translarna for Duchenne Muscular Dystrophy.

On the 8th of December 2017, representatives of Muscular Dystrophy Ireland met with the Minister for Health, to discuss the issues of access to Translarna for our young members.

Muscular Dystrophy Ireland
(A Company Limited by Guarantee and not having Share Capital)

Directors' report (continued)

NEWSLETTER

The Muscular Dystrophy Ireland News Update is a newsletter for the members of Muscular Dystrophy Ireland and includes articles about issues of interest to people affected by the condition, including research updates, articles on entitlements and holidays, photographs and reports on youth clubs and Muscular Dystrophy Ireland events such as conferences and fundraising events.

Three high quality colour editions of the newsletter were distributed to Members and supporters of Muscular Dystrophy Ireland via post, email and through our website www.mdi.ie.

SOCIAL MEDIA

Muscular Dystrophy Ireland manages social media accounts across 3 platforms amassing a significant following on Facebook (over 5000) and Twitter (over 1800). In 2017 Muscular Dystrophy Ireland began using Instagram as another method of communicating with Members and potential supporters.

FAMILY SUPPORT

Muscular Dystrophy Ireland offers family support service to families nationwide. The aim of the Family Support Team is to support families from diagnosis right through to bereavement. They promote, encourage and advocate for independent decision making by the members in keeping with the Muscular Dystrophy Ireland ethos.

The Role of the Family Support Team is to provide a quality service which best meets the varied needs of Muscular Dystrophy Ireland members.

The Family Support Team provides a range of information and support services to include: -

- Phone support
- Home visits
- Support and Social Groups
- Bereavement Support
- Interaction with Health and Social Care professionals
- Attendance at Case Conferences
- Counselling referrals
- Provision of information in relation to entitlements, health, housing and education

Muscular Dystrophy Ireland
(A Company Limited by Guarantee and not having Share Capital)

Directors' report (continued)

CLINICS

Muscular Dystrophy Ireland's Clinic Co-Ordinator attended the following clinics in 2017: -

Central Remedial Clinic
Tallaght Hospital
Beaumont Hospital
Temple Street Hospital

There were 57 Clinics in 2017.

Muscular Dystrophy Ireland's Clinic Co-ordinator was instrumental in the development of a new integrated care pathway for children and families with a neuromuscular diagnosis. This involved facilitating focus groups with members of Muscular Dystrophy Ireland and organising a National Parents Information Day on the 16th of September 2017 in the Croke Park Hotel to review the first draft of the care plan.

RESPITE SERVICES

The respite service is an essential support for people living with muscular dystrophy and their families.

Muscular Dystrophy Ireland Definition of Respite:

Respite care is short-term care that enables a family take a break from the daily caring role. Respite care can occur in the family home or in a variety of out-of-home settings, and can occur for any length of time depending on the needs of the family, and resources available. Muscular Dystrophy Ireland recognises that the person/child with muscular dystrophy and family members both need to avail of respite care services in order to maintain physical health and emotional wellbeing.

The respite services include:

1. Personal Assistant Services
2. Family Support Services
3. Six Respite Holiday Camps
4. Youth Services
5. Power Soccer Support
6. Adult Social Services
7. Transport Services
8. Counselling

Personal Assistant and in-home respite hours provided in 2017:

12,628 hours provided by Muscular Dystrophy Ireland Personal Assistants (12,960 hours provided in 2016).

1,120 hours through external agencies (IWA, CIL, Bluebird, Home Instead etc.) (2,268 hours provided in 2016).

3,538 hours provided to support Respite Holiday Programme (4,512 hours provided in 2016).

A total of 17,286 respite hours in 2017 (19,740 hours in 2016)

34 members received a personal assistant or in-home respite support.

65 members benefited from personal assistant support on Respite Holiday Programme

Muscular Dystrophy Ireland
(A Company Limited by Guarantee and not having Share Capital)

Directors' report (continued)

YOUTH RESPITE SERVICE

The overall aim of the Muscular Dystrophy Ireland Youth Service is the empowerment of our young members.

The specific aims of the Muscular Dystrophy Ireland Youth Work Programme are as follows: -

- To empower our young members
- To encourage meaningful participation
- To provide an educational aspect
- To promote equality of opportunity
- To provide respite for parents and siblings

Youth workers support, encourage and enable our young members to get out and about in their communities. Through our youth clubs, social outings and camps, members have the opportunity to make friends and maintain friendships already made. The peer support that is both given and received is invaluable.

On 2nd November 2017, the youth respite workers arranged a day at Mondello Park for their members. This gave members the opportunity to drive a car in a safe environment and then to experience a lap in a high speed Porsche. This was suitable for various abilities and was a unique experience for members. 14 members attended along with some parents and siblings.

Other activities organised by the youth services included:-

- Assisting with School Tours .
- Educational visits to Aras an Uachtaráin, Kilmainham Gaol, Newbarn Farm, Collon Military Museum, Dublin Zoo.
- A Confidence Building Workshop.
- Creative workshops such as, film making workshop, t-shirt making and arts and crafts.
- Attending concerts.
- Attending Football and Rugby Matches.
- Physical activities including canoeing, rock climbing, swimming, bowling, adaptive sports day

RESPITE HOLIDAY PROGRAMME

Muscular Dystrophy Ireland continues to develop the Respite Holiday Programme each year and in 2017 five respite breaks were held in Kilcuan, Galway and one youth respite camp took place in Share Discovery Village, Fermanagh.

In total 65 members participated in the Respite Holiday Programme during 2017.

The Respite Holiday Programme provides an invaluable service to members and families by providing a respite break not only for the member, but the families, parents and siblings.

Muscular Dystrophy Ireland
(A Company Limited by Guarantee and not having Share Capital)

Directors' report (continued)

HOME FROM HOME APARTMENT

2017 was again a busy year for the Home from Home Facility. The facility provided accommodation for over 700 guests (2016 - 661 guests) including members of Muscular Dystrophy Ireland and other organisations, such as Cheshire Home, Enable Ireland, Ataxia Ireland, St. John of Gods, Brothers of Charity, Muscular Dystrophy UK, Duchenne UK, and Muscular Dystrophy Denmark.

In February work was completed on building works carried out to increase the size of the living room area and lobby area of the facility. Work carried out in 2017 is the culmination of building project which saw the installation of ramp access, storage and opening up of the living areas of the Home from Home thus enabling the facility to maintain the high standards in universal access and design for all people with disabilities.

In November 2017, the Muscular Dystrophy Ireland Home from Home Facility received a renewed Bord Failte Four Star rating for the year.

ROOM HIRE AND TRAINING

The Boardroom has been used by several different organisations for their management meetings and community activities. This allows organisations to have a facility that meets their needs and provides access for all their membership. The groups that have used our building during 2017 are diverse, they have included Enable Ireland, The Salvation Army, Lucan Disability Action Group, The Ballyfermot Partnership, Post-Polio Support Group, Disabled Drivers Association, Ataxia Foundation Ireland and many others.

Throughout 2017 the Boardroom has been promoted as a training facility. This has created a large increase in numbers of training organisations using the building for training purposes. We have continued our relationship with Ballyfermot Senior College and Clondalkin College of Further Education which we provide Manual Handling training to all their Social Care students. Over 300 people in the local community benefited from the use of the Muscular Dystrophy Ireland boardroom in 2017.

TRANSPORT

Over the years Muscular Dystrophy Ireland has built up a transport fleet that covers the whole country. The transport service is co-ordinated by the Driver / Transport Coordinator based in Muscular Dystrophy Ireland Head Office. There are two full time buses dedicated to transporting members to and from clinics, hospital appointments, transport links, social outings and dropping Muscular Dystrophy Ireland loan equipment such as hoists or wheelchairs to hotels or members' residences.

Muscular Dystrophy Ireland buses are used by Youth Workers to carry out daily respite and youth work activities. There is currently a fleet of eleven buses operating nationwide.

In 2017 there were three dedicated drivers who provided a transport service to members with a total of 1,492 journeys undertaken.

Muscular Dystrophy Ireland
(A Company Limited by Guarantee and not having Share Capital)

Directors' report (continued)

RESEARCH

One of Muscular Dystrophy Ireland's aims is to fund and support research relating to muscular dystrophy. This includes biomedical research, which looks at what happens in the body when someone has muscular dystrophy, or identifies potential therapies. It also includes social research, which examines issues like education and quality of life.

In 2017 Muscular Dystrophy Ireland continued to fund medical research through the direct funding of a project in Maynooth University. Two further projects are co-funded via the Collagen VI Alliance in Newcastle University and the Rizzoli Orthopaedic Institute, Bologna. Muscular Dystrophy Ireland were successful with two grant applications via The Health Research Board and Medical Research Charities Group Joint Funding Scheme in 2017. This research will take place in Maynooth University and Oxford University. Both projects receive 50% funding from the HRB and 50% funding from the charity and received continued financial support from Muscular Dystrophy Ireland in 2017.

FUNDRAISING AND PUBLIC RELATIONS

Fundraising is an essential part of Muscular Dystrophy Ireland's organisation, supporting the continued provision of respite support services, medical research, as well as the Home from Home Facility.

Muscular Dystrophy Ireland acknowledges the wonderful support which it continues to receive from members, families, supporters and volunteers.

Highlights of Fundraising Campaigns 2017

Big Ireland Quiz
Bikefest
Dundalk Family Fun Run
Loughhill Walking Club
LoveMDI
Sandra's Motorcycle Run
Tesco Collection Day
VHI Mini Marathon

MAJOR RISKS FACING THE ORGANISATION

The Executive Committee are responsible for ensuring that the major risks facing the organisation are appropriately managed. During the year the major risks facing the organisation as identified by the Executive Committee and Management have been reviewed and their potential impact assessed. Policy and Procedures are in place to identify the risks facing the organisation taking into account the financial climate, changes in society and attitudes which reflect how the organisation operates and changes in law and technology. In particular expenditure across all areas has been reviewed in the light of a decrease in state funding and the uncertainty of a fundraising income.

Muscular Dystrophy Ireland
(A Company Limited by Guarantee and not having Share Capital)

Directors' report (continued)

FUTURE DEVELOPMENTS

The Strategic Planning process is underway. The Strategic Plan will specifically focus on key components of the organisation's vision, structure, services and activities. In 2018 meetings will be held regionally with members, staff and volunteers to ensure Muscular Dystrophy Ireland's strategic plan reflects the changing needs of the members.

Muscular Dystrophy Ireland will continue to strengthen the governance and regulation of the organisation to ensure compliance with relevant regulatory bodies.

Muscular Dystrophy Ireland will continue to contribute to national and international research led by our Research Committee.

Muscular Dystrophy Ireland will commence refurbishment of the Home from Home Facility following corporate donations from Aviva and SMBC Aviation Capital.

Ongoing specific goals for 2018: -

Ensure Website, Database and IT Technology are compliant with GDPR statutory obligations.
Continued engagement on Social Media Platforms to enhance communications with members, staff and stakeholders.
Continue to build on Corporate Partnerships.
Explore and develop Fundraising opportunities.
Continue Professional Development and Training Programme for staff which commenced in 2017.
Expansion of Board to enhance and complement existing skills and experience.
Continue work on a self-advocacy toolkit for members.
Research committee to focus on the development of a neuromuscular patient registry.

OTHER INCOMING RESOURCES

In line with many charities, Muscular Dystrophy Ireland receives goods, services and facilities free of charge or at reduced market rates. During 2017, Muscular Dystrophy Ireland received material goods and services to the value of €6,200 free of charge and this value has been incorporated into the financial statements for 2017.

Muscular Dystrophy Ireland has no reliable basis to measure the value to the organisation of these goods and services.

RESERVES

Muscular Dystrophy Ireland has a Reserves Policy which is reviewed each year. Muscular Dystrophy Ireland has free reserves at 31st December 2017, and it also has restricted reserves at 31st December 2017.

Formal policy on reserves was agreed at the meeting of the Executive Committee on 3rd April 2017.

It states:

The Board has set a reserves policy which requires:

Reserves be maintained at a level which ensures that Muscular Dystrophy Ireland's core activities could continue during a period of unforeseen difficulty equivalent to six months Core Funding.

A proportion of reserves be maintained in a readily realisable form.

Muscular Dystrophy Ireland
(A Company Limited by Guarantee and not having Share Capital)

Directors' report (continued)

Accounting records

The measures taken by the directors to secure compliance with the requirements of sections 281 to 285 of the Companies Act 2014 with regard to the keeping of accounting records are the implementation of necessary policies and procedures for recording transactions, the employment of competent accounting personnel with appropriate expertise and the provision of adequate resources to the financial function. The accounting records of the company are located at its registered office

Relevant audit information

In the case of each of the persons who are directors at the time this report is approved in accordance with section 332 of Companies Act 2014:

- so far as each director is aware, there is no relevant audit information of which the company's statutory auditors are unaware, and
- each director has taken all the steps that he or she ought to have taken as a director in order to make himself or herself aware of any relevant audit information and to establish that the company's statutory auditors are aware of that information.

This report was approved by the board of directors on 28 May 2018 and signed on behalf of the board by:

Director

GARRY TONER

Director



Muscular Dystrophy Ireland
(A Company Limited by Guarantee and not having Share Capital)

Directors' responsibilities statement

The directors are responsible for preparing the directors report and the financial statements in accordance with applicable Irish law and regulations.

Irish company law requires the directors to prepare financial statements for each financial year. Under the law, the directors have elected to prepare the financial statements in accordance with Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" issued by the Financial Reporting Council, and promulgated by the Institute of Chartered Accountants in Ireland. Under company law, the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the assets, liabilities and financial position of the company as at the financial year end date and of the profit or loss of the company for the financial year and otherwise comply with the Companies Act 2014.

In preparing these financial statements, the directors are required to:

- select suitable accounting policies and then apply them consistently;
- make judgments and accounting estimates that are reasonable and prudent;
- state whether the financial statements have been prepared in accordance with applicable accounting standards, identify those standards, and note the effect and the reasons for any material departure from those standards; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for ensuring that the company keeps or causes to be kept adequate accounting records which correctly explain and record the transactions of the company, enable at any time the assets, liabilities, financial position and profit or loss of the company to be determined with reasonable accuracy, enable them to ensure that the financial statements and directors report comply with the Companies Act 2014 and enable the financial statements to be audited. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

**Independent auditor's report to the members of
Muscular Dystrophy Ireland**

Opinion

We have audited the financial statements of Muscular Dystrophy Ireland for the year ended 31 December 2017 which comprise the profit and loss account, Statement of Financial Position, statement of changes in equity, statement of cash flows and related notes. The relevant financial reporting framework that has been applied in their preparation is the Companies Act 2014 and FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland issued by the Financial Reporting Council.

In our opinion the financial statements:

- give a true and fair view of the assets, liabilities and financial position of the company as at 31 December 2017 and of its surplus for the year then ended; and
- are prepared, in all material respects, in accordance with Irish law and FRS 102, the Financial Reporting Standard applicable in the UK and Republic of Ireland issued by the Financial Reporting Council.

Basis for Opinion

We conducted our audit in accordance with International Standards on Auditing (Ireland) (ISAs (Ireland)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the company in accordance with ethical requirements that are relevant to our audit of financial statements in Ireland, including the Ethical Standard issued by the Irish Auditing and Accounting Supervisory Authority (IAASA). We have fulfilled our other responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

We have nothing to report in respect of the following matters in relation to which ISAs (Ireland) require us to report to you where

- the directors' use of the going concern basis of accounting in the preparation of the financial statements is not appropriate; or
- the directors have not disclosed in the financial statements any identified material uncertainties that may cast significant doubt about the company's ability to continue to adopt the going concern basis of accounting for a period of at least twelve months from the date when the financial statements are authorised for issue.

Other Information

the directors are responsible for the other information. The other information comprises the information included in the annual report other than the financial statements and our Auditor's Report thereon. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard

**Independent auditor's report to the members of
Muscular Dystrophy Ireland (continued)**

Opinions on other matters prescribed by the Companies Act 2014

- in our opinion, the information given in the directors' report for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- in our opinion, the directors' report is consistent with the financial statements and has been prepared in accordance with the Companies Act 2014 and;
- We have obtained all the information and explanations which we consider necessary for the purposes of our audit.

In our opinion the accounting records of the company were sufficient to permit the financial statements to be readily and properly audited and the financial statements are in agreement with the accounting records.

Matters on which we are required to report by exception

In the light of our knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified material misstatements in the directors' report.

The Companies Act 2014 requires us to report to you if, in our opinion, the disclosures of directors' remuneration and transactions required by sections 305 to 312 of the Act are not made. We have nothing to report in this regard.

Respective responsibilities of management and those charged with governance for the financial statements.

As explained more fully in the directors' responsibilities statement, management is responsible for the preparation of the financial statements in accordance with Irish law and FRS 102, the Financial Reporting Standard applicable in the UK and Republic of Ireland issued by the Financial Reporting Council and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Company's financial reporting process.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an Auditor's Report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (Ireland) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with ISAs, we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than one from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

**Independent auditor's report to the members of
Muscular Dystrophy Ireland (continued)**

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the company to continue to cease as a going concern.



Raymond Hunt
For and on behalf of
Hunt & Company Accountants Limited
Chartered Certified Accountants & Statutory Auditors
52 Manor Street
Dublin 7

29 May 2018

Muscular Dystrophy Ireland
(A Company Limited by Guarantee and not having Share Capital)

Statement of Finance Activities
for the financial year ended 31 December 2017

		Unrestricted Funds	Restricted Funds	Total Funds	Total Funds
		2017	2017	2017	2016
	Notes	€	€	€	€
INCOMING RESOURCES					
Incoming resources from					
Voluntary Income					
Donations and Fundraising		186,137	-	186,137	161,338
Subscriptions		4,020	-	4,020	4,085
Incoming resources from charitable resources					
Grants and other service contract income	4	-	1,272,986	1,272,986	1,354,475
Other income		40,822	14,004	54,826	41,753
Investment income	6	2,362	-	2,362	4,779
Amortised Grants		-	-	-	-
Total Incoming resources	3	<u>233,341</u>	<u>1,286,990</u>	<u>1,520,331</u>	<u>1,566,430</u>
RESOURCES EXPENDED					
Cost of generating funds					
Cost of generating voluntary income					
Public Relations, Awareness & Fundraising		36,140	64,389	100,529	103,035
Charitable activities					
Respite Care Services		120,114	1,164,106	1,284,220	1,398,825
POBAL		-	-	-	18,637
Other		34,050	-	34,050	24,024
Governance costs		<u>18,527</u>	<u>21,991</u>	<u>40,518</u>	<u>38,051</u>
Total resources expended	3	<u>208,831</u>	<u>1,250,486</u>	<u>1,459,317</u>	<u>1,582,572</u>
Net incoming/(outgoing) resources		<u><u>24,510</u></u>	<u><u>36,504</u></u>	<u><u>61,014</u></u>	<u><u>(16,142)</u></u>

The financial statements were approved by the board on 28 May 2018 and signed on its behalf by
On behalf of the board

Director

GARRY TONEK

Director



Muscular Dystrophy Ireland
(A Company Limited by Guarantee and not having Share Capital)

Statement of financial position
As at 31 December 2017

	Note	2017 €	€	2016 €	€
Fixed assets					
Tangible assets	7	224,923		178,161	
Financial assets	8	1,589,111		1,589,111	
			1,814,034		1,767,272
Current assets					
Support group		6,592		15,027	
Debtors	9	98,129		137,557	
Investments		450,000		450,000	
Designated fund		101,223		101,213	
Restricted Trust and Research funds	15	664,486		698,448	
Cash at bank and in hand		582,746		605,384	
		1,903,176		2,007,629	
Creditors: amounts falling due within one year	10	(120,197)		(152,082)	
Net current assets		1,782,979		1,855,547	
Total assets less current liabilities		3,597,013		3,622,819	
Creditors: amounts falling due after more than one year	11	(156,775)		(208,732)	
Net assets		3,440,238		3,414,087	
Capital and reserves					
Restricted fund	15	842,471		840,830	
Unrestricted fund	15	2,597,767		2,573,257	
Members funds	15	3,440,238		3,414,087	

The notes on pages 21 to 34 form part of these financial statements.

Muscular Dystrophy Ireland
(A Company Limited by Guarantee and not having Share Capital)

Statement of financial position (continued)
As at 31 December 2017

These financial statements were approved by the board of directors on 28 May 2018 and signed on behalf of the board by:

Director

GARRY TONER

Director



The notes on pages 21 to 34 form part of these financial statements.

Muscular Dystrophy Ireland
(A Company Limited by Guarantee and not having Share Capital)

Statement of cash flows
Financial year ended 31 December 2017

	2017	2016
	€	€
Cash flows from operating activities		
Net incoming/(outgoing) resources for the financial year	61,014	(16,142)
<i>Adjustments for:</i>		
Depreciation of tangible assets	17,395	9,776
Bank interest and Prize bond income	(2,362)	(4,779)
Accrued expenses/(income)	4,470	(42,470)
<i>Changes in:</i>		
Trade and other debtors	47,863	1,106
Trade and other creditors	(88,312)	180,863
Cash generated from operations	<u>40,068</u>	<u>128,354</u>
Net cash from operating activities	<u>40,068</u>	<u>128,354</u>
Cash flows from investing activities		
Purchase of tangible assets	(64,157)	(28,401)
Bank interest & Prize bond income received	2,362	4,779
Capital funds movement	(34,863)	(25,552)
Net cash used in investing activities	<u>(96,658)</u>	<u>(49,174)</u>
Net increase/(decrease) in cash and cash equivalents	(56,590)	79,180
Cash and cash equivalents at beginning of financial year	1,855,045	1,775,865
Cash and cash equivalents at end of financial year	<u>1,798,455</u>	<u>1,855,045</u>

Muscular Dystrophy Ireland
(A Company Limited by Guarantee and not having Share Capital)

Notes to the financial statements
Financial year ended 31 December 2017

1. Statement of compliance

These financial statements have been prepared in compliance with FRS 102, 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.

2. Accounting policies

Basis of preparation

The financial statements have been prepared on the historical cost basis, as modified by the revaluation of certain financial assets and liabilities and investment properties measured at fair value through profit or loss.

The financial statements are prepared in Euro, which is the functional currency of the entity.

Support Groups

The Company had six regional support groups with the Mountbellow, & Dublin branches closing during the year. Donegal, Midlands, Kerry & South East support groups are in the process of closing, following a full review of the structures and activities of said support groups. None of the regional support groups returned their financial details for 2017 to Muscular Dystrophy Ireland. The net incoming/ (outgoing) resources of the regional support groups are not included in the Statement of Financial Activities.

Taxation

The company is exempt from Corporation Tax as it has been granted Charitable Status by the Revenue Commissioners under Charity Number. 6489

Tangible assets

Tangible assets are initially recorded at cost, and are subsequently stated at cost less any accumulated depreciation and impairment losses.

Any tangible assets carried at revalued amounts are recorded at the fair value at the date of revaluation less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

An increase in the carrying amount of an asset as a result of a revaluation, is recognised in other comprehensive income and accumulated in capital and reserves, except to the extent it reverses a revaluation decrease of the same asset previously recognised in profit or loss. A decrease in the carrying amount of an asset as a result of revaluation is recognised in other comprehensive income to the extent of any previously recognised revaluation increase accumulated in capital and reserves in respect of that asset. Where a revaluation decrease exceeds the accumulated revaluation gains accumulated in capital and reserves in respect of that asset, the excess shall be recognised in profit or loss.

Muscular Dystrophy Ireland
(A Company Limited by Guarantee and not having Share Capital)

Notes to the financial statements (continued)
Financial year ended 31 December 2017

Depreciation

Depreciation is calculated so as to write off the cost or valuation of an asset, less its residual value, over the useful economic life of that asset as follows:

Plant and machinery	- 20%
Fittings fixtures and equipment	- 20%
Ramp	- 4%
Motor vehicles	- 20%

If there is an indication that there has been a significant change in depreciation rate, useful life or residual value of tangible assets, the depreciation is revised prospectively to reflect the new estimates.

Financial assets

Financial assets are initially recorded at cost, and subsequently stated at cost less any provision for diminution in value. Listed investments are measured at fair value with changes in fair value being recognised in profit or loss.

Impairment

A review for indicators of impairment is carried out at each reporting date, with the recoverable amount being estimated where such indicators exist. Where the carrying value exceeds the recoverable amount, the asset is impaired accordingly. Prior impairments are also reviewed for possible reversal at each reporting date.

When it is not possible to estimate the recoverable amount of an individual asset, an estimate is made of the recoverable amount of the cash-generating unit to which the asset belongs. The cash-generating unit is the smallest identifiable group of assets that includes the asset and generates cash inflows that are largely independent of the cash inflows from other assets or groups of assets.

Muscular Dystrophy Ireland
(A Company Limited by Guarantee and not having Share Capital)

Notes to the financial statements (continued)
Financial year ended 31 December 2017

Government grants

Government grants are recognised at the fair value of the asset received or receivable. Grants are not recognised until there is reasonable assurance that the company will comply with the conditions attaching to them and the grants will be received.

Government grants are recognised using the accrual model and the performance model.

Under the accrual model, government grants relating to revenue are recognised on a systematic basis over the periods in which the company recognises the related costs for which the grant is intended to compensate. Grants that are receivable as compensation for expenses or losses already incurred or for the purpose of giving immediate financial support to the entity with no future related costs are recognised in income in the period in which they become receivable.

Grants relating to assets are recognised in income on a systematic basis over the expected useful life of the asset. Where part of a grant relating to an asset is deferred, it is recognised as deferred income and not deducted from the carrying amount of the asset.

Under the performance model, where the grant does not impose specified future performance-related conditions on the recipient, it is recognised in income when the grant proceeds are received or receivable. Where the grant does impose specified future performance-related conditions on the recipient, it is recognised in income only when the performance-related conditions have been met. Where grants received are prior to satisfying the revenue recognition criteria, they are recognised as a liability.

Fund accounting

Restricted Funds:

Restricted funds represent Grants and other funders which can only be used for the particular purposes specified by the donors. Such purposes are within the overall objectives of Muscular Dystrophy Ireland.

Unrestricted Funds:

Unrestricted Funds represents amounts which are expendable at the discretion of the National Executive Committee, in furtherance of the objectives of Muscular Dystrophy Ireland.

Muscular Dystrophy Ireland
(A Company Limited by Guarantee and not having Share Capital)

Notes to the financial statements (continued)
Financial year ended 31 December 2017

3. Incoming Resources/Resources Expended	2017	2016
	€	€
Incoming Resources		
Fundraising - National Office and Regional	97,333	109,645
Respite Care Services	1,270,787	1,335,822
MDI Centre	63,407	50,618
Donations	88,804	51,693
POBAL	-	18,652
Total Incoming Resources	1,520,331	1,566,430
Resources Expended		
Fundraising - National Office and Regional	100,529	103,035
Respite Care Services (See Note below)	1,284,220	1,398,825
MDI Centre	34,050	19,557
POBAL	-	18,637
Other	-	4,467
Governance Costs - National and Regional	40,518	38,051
Total Resources Expended	1,459,317	1,582,572
Net Incoming/(Outgoing) Resources	61,014	(16,142)

Included in respite care services resources expended is an amount of €351,005. (2016 : €355,915) in relation to support costs.

Net Incoming/(Outgoing) Resources

The net incoming/(outgoing) resources for the year are stated after charging	2017	2016
	€	€
Depreciation of tangible assets	17,395	9,776
Auditors' remuneration	3,629	3,629
and after crediting:		
Bank interest & Prize bond income	2,362	4,779

Muscular Dystrophy Ireland
(A Company Limited by Guarantee and not having Share Capital)

Notes to the financial statements (continued)
Financial year ended 31 December 2017

4. Funding and Grants

HSE - Statutory Funding - Service Level Agreements

Purpose of Funding: Pay and Operational Costs

Term: Expires 31 December 2017

Restrictions on use: Core Charitable and Support Services

Funding received in the year ended 31st December 2017

	2017	2016
	€	€
CHO Area 1 (North Western Area Health Board)	3,288	3,288
CHO Area 2 (Western Area Health Board)	11,000	11,000
CHO Area 4 (Southern Area Health Board)	91,251	91,251
CHO Area 5 (South Eastern Area Health Board)	10,740	10,739
CHO Area 6 (East Coast Area Health Board)	19,584	19,584
CHO Area 7 (South Western Area Health Board)	45,505	45,505
CHO Area 8 (Midlands Area Health Board)	52,635	52,631
CHO Area 1 & 8 (Cavan Monaghan, Louth Meath)	79,440	79,445
CHO Area 9 (Northern Area Health Board)	767,620	767,709
	<u>1,081,063</u>	<u>1,081,152</u>

Funding expended in the year ended 31st December 2017

Respite Pay Costs including pension contributions and Employers' PRSI	558,248	599,806
Support Pay Costs including pension contributions and Employers' PRSI	229,016	187,937
Respite Care Services Non Pay Costs	134,888	155,341
Communications	5,447	4,648
Utilities	5,069	6,947
Rent of regional offices	16,613	16,504
Support costs	98,704	92,810
Professional Fees:-		
HR Fees	10,763	23,469
Audit Fees	1,210	3,629
Pension Administration Fees	649	649
Governance costs	9,369	17,847
	<u>1,069,976</u>	<u>1,109,587</u>
Surplus/(Deficit)	<u>11,087</u>	<u>(28,435)</u>

Muscular Dystrophy Ireland
(A Company Limited by Guarantee and not having Share Capital)

Notes to the financial statements (continued)
Financial year ended 31 December 2017

HSE - Direct Services - Service Level Agreements
Purpose of Funding: Direct Support Services Provision
Term: Expires 31st December 2017
Restrictions on Use: Direct Services to Members

Funding received in the year ended 31st December 2017

	2017	2016
	€	€
CHO Area 9 (Northern Area Health Board)	57,020	80,060
CHO Area 7 (South Western Area Health Board)	47,530	33,890
CHO Area1 (North Western Area Health Board)	16,046	15,702
CHO Area 6 (East Coast Area Health Board)	1,240	1,358
	<u>121,836</u>	<u>131,010</u>

Funding expended in the year ended 31st December 2017

Direct Services Pay Costs	104,126	117,793
Support and Training Costs	2,152	3,660
	<u>106,278</u>	<u>121,453</u>
 Surplus	 <u>15,558</u>	 <u>9,557</u>

Muscular Dystrophy Ireland
(A Company Limited by Guarantee and not having Share Capital)

Notes to the financial statements (continued)
Financial year ended 31 December 2017

HSE- National Lottery Funding

Purpose of Funding: Short Term Respite and Summer Respite Programme

Term: Expires 31st December 2017

Restrictions on use: Short Term Respite and Summer Respite Programme

Funding received in the year ended 31st December 2017

	2017	2016
	€	€
CHO Area 1 (North Western Area Health Board)	3,250	9,950
CHO Area 2 (Western Area Health Board)	9,000	8,500
CHO Area 4 (Southern Area Health Board)	-	2,500
CHO Area 5 (South Eastern Area Health Board)	-	6,000
CHO Area 6 (East Coast Area Health Board)	-	13,000
CHO Area 7 (South Western Area Health Board)	10,000	14,000
CHO Area 8 (Midlands Area Health Board - Including Louth Meath)	12,000	13,000
CHO Area 9 (Northern Area Health Board)	11,800	8,800
	<u>46,050</u>	<u>75,750</u>

Funding expended in the year ended 31st December 2017

Short Term Respite	27,550	40,550
Summer Respite Programme	18,500	35,200
	<u>46,050</u>	<u>75,750</u>
Surplus	<u>-</u>	<u>-</u>

POBAL

	2017	2016
	€	€
SNNO 2011 - 2014 - Extended	-	18,653
	<u>-</u>	<u>18,653</u>

Muscular Dystrophy Ireland
(A Company Limited by Guarantee and not having Share Capital)

Notes to the financial statements (continued)
Financial year ended 31 December 2017

	2017	2016
	€	€
DSP Support Grant		
Employment Support Scheme	<u>22,818</u>	<u>32,436</u>
Other Grants	2017	2016
	€	€
TUSLA - Conselling Support Services	2,200	2,200
Department of Children & Youth Affairs - Youth Respite Equipment Grant	-	293
Galway Co. Council - Youth Service Equipment Grant	700	1,100
Galway Co. Council - Swimming Grant	-	564
Heineken Fund - Southern Area Youth Respite Services	-	1,260
West Limerick Independant Living - Intern Support services	-	3,211
Limerick Insitute of Technology - Intern Support Services	<u>(1,681)</u>	<u>6,846</u>
	<u>1,219</u>	<u>15,474</u>
	<u>1,272,986</u>	<u>1,354,475</u>

Muscular Dystrophy Ireland
(A Company Limited by Guarantee and not having Share Capital)

Notes to the financial statements (continued)
Financial year ended 31 December 2017

5. Staff costs

Support Services	82	83
Operation Service	5	4
	87	87

The aggregate payroll costs incurred during the financial year were:

	2017	2016
	€	€
Wages and salaries	980,852	1,027,838
Pension costs	10,062	4,819
	990,914	1,032,657

The number of employees whose employment, excluding employer pension contributions, was greater than €65,000 is below:

	2017	2016
	Number	Number
€65,000 - €75,000	-	-
€75,000 - €85,000	-	-
€85,000 - €95,000	1	1

Pension costs

The Company operates a defined contribution pension scheme. The scheme and its assets are held separately from those of the company in an independent administered fund with Aviva Life Assurance Company.

6. Bank interest & Prize bond income

	2017	2016
	€	€
Bank interest & Prize bond income	2,362	4,779

Muscular Dystrophy Ireland
(A Company Limited by Guarantee and not having Share Capital)

Notes to the financial statements (continued)
Financial year ended 31 December 2017

7. Tangible assets

	Office fit-out	Fixtures, fittings and equipment	Motor vehicles	Total
	€	€	€	€
Cost				
At 1 January 2017	277,492	180,510	365,686	823,688
Additions	10,877	53,280	-	64,157
Disposals	-	-	(23,258)	(23,258)
At 31 December 2017	<u>288,369</u>	<u>233,790</u>	<u>342,428</u>	<u>864,587</u>
Depreciation				
At 1 January 2017	258,471	21,370	365,686	645,527
Charge for the financial year	8,900	8,495	-	17,395
Disposals	-	-	(23,258)	(23,258)
At 31 December 2017	<u>267,371</u>	<u>29,865</u>	<u>342,428</u>	<u>639,664</u>
Carrying amount				
At 31 December 2017	<u>20,998</u>	<u>203,925</u>	<u>-</u>	<u>224,923</u>
	Office fit-out	Fixtures, fittings and equipment	Motor vehicles	Total
	€	€	€	€
Cost				
At 1 January 2016	271,101	158,500	365,686	795,287
Additions	6,391	22,010	-	28,401
Disposals	-	-	-	-
At 31 December 2016	<u>277,492</u>	<u>180,510</u>	<u>365,686</u>	<u>823,688</u>
Depreciation				
At 1 January 2016	248,695	21,370	365,686	635,751
Charge for the financial year	9,776	-	-	9,776
Disposals	-	-	-	-
At 31 December 2016	<u>258,471</u>	<u>21,370</u>	<u>365,686</u>	<u>645,527</u>
Carrying amount				
At 31 December 2016	<u>19,021</u>	<u>159,140</u>	<u>-</u>	<u>178,161</u>

Muscular Dystrophy Ireland
(A Company Limited by Guarantee and not having Share Capital)

Notes to the financial statements (continued)
Financial year ended 31 December 2017

8. Financial assets

	Investments in Subsidiary	Total
	€	€
Cost		
At 1 January 2017 and 31 December 2017	1,589,111	1,589,111
	<u> </u>	<u> </u>
Provision for diminution in value		
At 1 January 2017 and 31 December 2017	-	-
	<u> </u>	<u> </u>
Carrying amount		
At 31 December 2017	1,589,111	1,589,111
	<u> </u>	<u> </u>
	Investments in Subsidiary	Total
	€	€
Cost		
At 1 January 2016 and 31 December 2016	1,589,111	1,589,111
	<u> </u>	<u> </u>
Provision for diminution in value		
At 1 January 2016 and 31 December 2016	-	-
	<u> </u>	<u> </u>
Carrying amount		
At 31 December 2016	1,589,111	1,589,111
	<u> </u>	<u> </u>

Muscular Dystrophy Ireland
(A Company Limited by Guarantee and not having Share Capital)

Notes to the financial statements (continued)
Financial year ended 31 December 2017

8. Financial assets (continued)

Muscular Dystrophy Ireland holds 100% of the share capital of the following company:

Company	Country of registration or Incorporation	Class of share
MDI House Limited	Ireland	Ordinary

MDI House Limited's principal activity is that it owns the property at 75 Lucan Road, Chapelizod, Dublin 20 which is a purpose built facility to specifically cater for the requirements of people with Muscular Dystrophy and allied neuromuscular conditions, and their families.

In the opinion of the directors, the value to Muscular Dystrophy Ireland of the unlisted investment is not less than the book amount shown above, having regard to the service potential of the underlying property.

9. Debtors

	2017	2016
	€	€
Grants and Income due	70,778	120,609
Stock of Fundraising material	-	1,523
Other debtors	1,542	1,160
Prepayments and accrued income	25,809	14,265
	<u>98,129</u>	<u>137,557</u>

10. Creditors: amounts falling due within one year

	2017	2016
	€	€
Other creditors	27,517	50,404
Tax and social insurance:		
PAYE and social welfare	35,350	48,818
Accruals	57,330	52,860
	<u>120,197</u>	<u>152,082</u>

Muscular Dystrophy Ireland
(A Company Limited by Guarantee and not having Share Capital)

Notes to the financial statements (continued)
Financial year ended 31 December 2017

11. Creditors: amounts falling due after more than one year

	2017	2016
	€	€
Deferred Donations & Legacy Income (Note 12)	136,580	160,000
Other creditors	-	14,153
Deferred income (Note 12A)	20,195	34,579
	156,775	208,732

12. Deferred Donations & Legacy income

	Deferred at 1 Jan 2017	Received in 2017	Amortised in 2017	Deferred at 31 Dec 2017
	€	€	€	€
Donations	110,000	-	33,420	76,580
Legacy income	50,000	10,000	-	60,000
	160,000	10,000	33,420	136,580

12A Deferred income

	Deferred at 1 Jan 2017	Received in 2017	Amortised in 2017	Deferred at 31 Dec 2017
	€	€	€	€
Department of Social Protection - Employee Support Services	16,217	-	16,217	-
CHO Area 8 (Louth Lottery Funding) - Respite Support Services	7,000	-	7,000	-
Other Funding - Support Services	11,362	17,020	8,187	20,195
	34,579	17,020	31,404	20,195

13. Commitments

The Company completed the Ramp Building Project during the year and it had at 31 December 2017 no future commitments.

14. Events after the end of the reporting period

There were no subsequent events after year end.

Muscular Dystrophy Ireland
(A Company Limited by Guarantee and not having Share Capital)

Notes to the financial statements (continued)
Financial year ended 31 December 2017

15. Equity Reserves

	Restricted Fund	Unrestricted Fund	Total
	€	€	€
At 1 January 2017	840,830	2,573,257	3,414,087
Movements during the year	36,504	24,510	61,014
Other	(34,863)	-	(34,863)
At 31 December 2017	<u>842,471</u>	<u>2,597,767</u>	<u>3,440,238</u>

The movement in restricted funds in the year were as follows:-

Restricted Fund	At start of year	Received during year	Expenditure during year	At end of year
	€	€	€	€
Research Fund	679,200	23,163	60,497	641,866
Trust Fund	20,111	7,480	4,971	22,620
Other	141,519	36,504	38	177,985
	<u>840,830</u>	<u>67,147</u>	<u>65,506</u>	<u>842,471</u>

Research Fund and Trust Fund consists of amounts received which can only be used for the purpose designated by Research and Trust Fund Committee.

Other restricted funds include funds received from HSE - Statutory Funding, National Lottery Funding and POBAL.

16. Related party

No related party transaction during the year.

17. Approval of financial statements

The board of directors approved these financial statements for issue on 28 May 2018.